Cargando…

Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus‐treated transplant recipients?

Detalles Bibliográficos
Autores principales:	Robertsen, Ida, Woillard, Jean‐Baptiste, Åsberg, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688523/ https://www.ncbi.nlm.nih.gov/pubmed/31144343 http://dx.doi.org/10.1111/bcp.13984

Ejemplares similares

Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
por: Gustavsen, Marte Theie, et al.
Publicado: (2020)

A Method for Evaluating Robustness of Limited Sampling Strategies—Exemplified by Serum Iohexol Clearance for Determination of Measured Glomerular Filtration Rate
por: Hovd, Markus, et al.
Publicado: (2023)

Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
por: Åsberg, Anders, et al.
Publicado: (2020)

Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients
por: Robertsen, Ida, et al.
Publicado: (2013)

Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients
por: Drevland, Ole Martin, et al.
Publicado: (2023)

Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients
por: Zhu, Huaijun, et al.
Publicado: (2022)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

Genotype-guided tacrolimus dosing in African American kidney transplant recipients
por: Sanghavi, K., et al.
Publicado: (2015)

Lower versus higher starting tacrolimus dosing in kidney transplant recipients
por: Chua, Justin C. M., et al.
Publicado: (2022)

Influence of ABCB1 gene polymorphism on concentration to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2021)

Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
por: Srinivas, Lekshmy, et al.
Publicado: (2021)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2022)

Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients
por: Tang, Jie, et al.
Publicado: (2017)

Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?
por: Krzyżowska, Kinga, et al.
Publicado: (2018)

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
por: Åsberg, Anders, et al.
Publicado: (2013)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

Tacrolimus Dose Requirement in Iranian Kidney Transplant Recipients within the First Three Weeks after Transplantation
por: Dashti-Khavidaki, S., et al.
Publicado: (2016)

Predicting model‐informed precision dosing: A test‐case in tacrolimus dose adaptation for kidney transplant recipients
por: Faelens, Ruben, et al.
Publicado: (2022)

Corrigendum: Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients
por: Tang, Jie, et al.
Publicado: (2018)

A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients
por: Tang, Jiang-Tao, et al.
Publicado: (2018)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

Why, When and How to Adjust Your P Values?
por: Jafari, Mohieddin, et al.
Publicado: (2019)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Dose-adjusted and dose/kg-adjusted concentrations of mycophenolic acid precursors reflect metabolic ratios of their metabolites in contrast with tacrolimus and cyclosporine
por: Hryniewiecka, Ewa, et al.
Publicado: (2019)

Importance of hematocrit for a tacrolimus target concentration strategy
por: Størset, Elisabet, et al.
Publicado: (2013)

Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study
por: Lenain, Rémi, et al.
Publicado: (2021)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients
por: Pei, Ling, et al.
Publicado: (2023)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

Massive pleural effusion in a renal transplant recipient on tacrolimus
por: Nayagam, L. S., et al.
Publicado: (2014)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7q5f5vdrs8an8ufectahftocnr